Exeltis USA Inc

General

Total Cases4
Active Cases2
Patents--
TypeOperating Company
Elite Ratings
--

Ratings

Experience
Grade
Trend
DCT
--
--
--
PTAB
--
--
--
CAFC
--
--
--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered
Case
Description
09/12/24
NOTICE requesting Clerk to remove Michael K. Nutter, Merritt Westcott, Corinne S. Hockman and Daniel P. Withers as co-counsel. Reason for request: no longer affiliated with the case. (Bilson, David) (Entered: 09/12/2024)
09/11/24
Joint letter to The Honorable Richard G. Andrews, from Jonathan A. Bell, regarding proposed final judgment. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2)(Bell, Jon) Modified on 9/12/2024 (nms). (Entered: 09/11/2024)
09/04/24
TRIAL OPINION: For the foregoing reasons, I find that Exeltis has proven by a preponderance of the evidence that Lupin infringes claim 14 of the '299 patent, claims 12 and 21 of the '632 patent, claim 29 of the '122 patent, claim 7 of the '249 patent, and claim 19 of the '487 patent. Lupin has failed to prove by clear and convincing evidence that the asserted claims are indefinite. Lupin has also failed to prove by clear and convincing evidence that claim 29 of the '122 patent and claim 7 of the '249 patent are invalid for lack of written description. Lastly, Lupin has failed to prove by clear and convincing evidence that the six asserted claims are invalid as obvious. Exeltiss evidence regarding objective indicia supports a finding of nonobviousness. The parties shall submit a final judgment consistent with this memorandum opinion within one week. Signed by Judge Richard G. Andrews on 9/4/2024. (nms) (Entered: 09/04/2024)
08/28/24
REDACTED VERSION of [365] Declaration of Brian Segers, by Chemo Iberica, S.A., Chemo Research, S.L., Exeltis USA, Inc., Laboratorios Leon Farma, S.A.. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2, # [3] Exhibit 3, # [4] Exhibit 4, # [5] Exhibit 5, # [6] Exhibit 6, # [7] Exhibit 7, # [8] Exhibit 8, # [9] Exhibit 9, # [10] Exhibit 10, # [11] Exhibit 11, # [12] Exhibit 12, # [13] Exhibit 13, # [14] Exhibit 14, # [15] Exhibit 15, # [16] Exhibit 16, # [17] Exhibit 17, # [18] Exhibit 18)(Bell, Jon) Modified on 8/29/2024 (nms). (Entered: 08/28/2024)
08/28/24
REDACTED VERSION of [364] Declaration of Salustiano Perez, by Chemo Iberica, S.A., Chemo Research, S.L., Exeltis USA, Inc., Laboratorios Leon Farma, S.A.. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2, # [3] Exhibit 3, # [4] Exhibit 4)(Bell, Jon) Modified on 8/29/2024 (nms). (Entered: 08/28/2024)
08/28/24
REDACTED VERSION of [363] Opening Brief in Support, by Chemo Iberica, S.A., Chemo Research, S.L., Exeltis USA, Inc., Laboratorios Leon Farma, S.A.. (Attachments: # [1] Exhibit 1, # [2] Exhibit 2)(Bell, Jon) (Entered: 08/28/2024)
08/28/24
REDACTED VERSION of [362] MOTION for Temporary Restraining Order and Preliminary Injunction Following the Expiration of the 30-Month Stay by Chemo Iberica, S.A., Chemo Research, S.L., Exeltis USA, Inc., Laboratorios Leon Farma, S.A.. (Attachments: # [1] Proposed Order)(Bell, Jon) (Entered: 08/28/2024)
08/27/24
NOTICE requesting Clerk to remove Dennis D. Gregory as co-counsel. Reason for request: no longer affiliated with the case. (Bilson, David) (Entered: 08/27/2024)
08/22/24
[SEALED] MULTI MEDIA DOCUMENT filed by Chemo Iberica, S.A., Chemo Research, S.L., Exeltis USA, Inc., Laboratorios Leon Farma, S.A. in the form of a USB drive containing Exhibits 2 and 4 to the Declaration at D.I. [364] and Sealed Exhibits 9, 10, 13, 15, and 16 to the Declaration at D.I. [365] . Filing related to [366] Notice of Filing Multi Media Materials (*Media on file in Clerk's Office). (nms) (Entered: 08/22/2024)
08/22/24
ORDER: The Motion for Temporary Restraining Order (D.I. [362] ) is GRANTED. The Court is in the final stages of issuing a trial opinion. The Court suggests that the parties await that decision before filing any more briefing on the pending motion for a preliminary injunction (see Order for further details). Signed by Judge Richard G. Andrews on 8/22/2024. (nms) (Entered: 08/22/2024)